Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
Agomab Therapeutics NV announced on August 10, 2026 that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors.1 The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.1
Board Chairman David Epstein said Marino brings extensive experience building, financing and leading innovative biotechnology companies through important stages of growth, while Naimish contributes deep expertise in clinical development, translational medicine and immunology.1
Garcia currently holds the top executive post at Dianthus Therapeutics (Nasdaq: DNTH). According to the release, he has led that company's transformation from a private biotechnology startup into a publicly traded, clinical-stage company with three product candidates in development and more than $1.6 billion in capital raised.1 His earlier career included senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals covering strategy, business development, commercialization and operations, along with commercial and strategic positions at Merck, Pfizer and Eli Lilly.1
Patel is currently Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP) and brings extensive experience in clinical development, translational medicine and immunology.1 He previously worked at Sanofi, where he most recently led the company's global immunology and inflammation development organization and oversaw development programs across respiratory, dermatology, gastroenterology and rheumatology.1 He also held roles at AstraZeneca and Vertex Pharmaceuticals and served on the faculty of Harvard Medical School and Beth Israel Deaconess Medical Center.1
Agomab also disclosed it will hold an Extraordinary General Shareholders' Meeting to obtain approval for consolidating and splitting outstanding pre-IPO warrants, adjusting each to reflect the share split completed with Agomab's February 2026 IPO.1 Both meetings are set for 2:30 PM CEST on September 11, 2026 in Antwerp, Belgium.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.